Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Nabi Biopharmaceuticals
ClinicalTrials.gov Identifier:
NCT00066989
First received: August 8, 2003
Last updated: May 10, 2012
Last verified: May 2012
  Purpose

The main objective will be to test the safety of two intravenous infusions of Altastaph, a human immunoglobulin product. The study will also test the ability of Altastaph to protect against S. aureus infection.


Condition Intervention Phase
Staphylococcal Infections
Drug: Staphylococcus aureus Immune Globulin (Human) 5%
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: A Double Blind, Randomized, Multicenter Stratified Study to Assess the Safety of an Intravenous Staphylococcus Aureus Immune Globulin (Human) [Altastaph] in Low-Birth-Weight-Neonates

Resource links provided by NLM:


Further study details as provided by Nabi Biopharmaceuticals:

Estimated Enrollment: 200
Study Start Date: July 2003
Study Completion Date: August 2004
Primary Completion Date: August 2004 (Final data collection date for primary outcome measure)
Detailed Description:

Survival of Very-Low-Birth-Weight (VLBW) infants (<1500g at birth) has improved dramatically, but these patients remain subject to significant morbidity and mortality due to Staphylococcus aureus infection. S. aureus infection is a relatively common event in VLBW neonates, occurring in approximately 3.4% of very low birth weight neonates and accounting for 15-20% of all infections in this patient population. This controlled study will assess the safety, pharmacokinetics, and preliminary efficacy of Altastaph in LBW neonates. The study will be stratified by birth weight and include up to 200 LBW neonates, 3 to 7 days of age.

  Eligibility

Ages Eligible for Study:   up to 7 Days
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

The subject must conform to all of the following (Inclusion Criteria):

  • Neonate with a birth weight between 501 and 1500 grams inclusive;
  • Between 3 and 7 days of age, inclusive, at the time of first infusion (Day 0);
  • Expected to survive at least 48 hours after infusion;
  • Free of overt systemic infection, as determined by history, physical examination, radiologic studies, or laboratory studies including microbiology data; clinical safety tests required can be completed up to three (3) days prior to the infusion of the study product;
  • Direct bilirubin less than or equal to 2.0 mg/dL;
  • Serum creatinine level of less than or equal to 2.0 mg/dL; and
  • Hemodynamically stabile; if the subject is receiving cardiac support including anti-arrhythmics, pressors, or cardiac pacing, the subject must be stable on that cardiac support and be expected not to require this support indefinitely.

The subject must not have any of the following (Exclusion Criteria):

  • Known HIV infection, as documented by maternal history or positive PCR in the infant;
  • Severe congenital anomaly or genetic disorder known to impact immune competence;
  • Prior administration of any immune globulin;
  • Any history, in the infant subject or its mother, of hypersensitivity or severe vasomotor reaction to any human blood product;
  • Cyanotic congenital heart disease; and
  • Central nervous system shunt
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Additional Information:
No publications provided

Responsible Party: Nabi Biopharmaceuticals
ClinicalTrials.gov Identifier: NCT00066989     History of Changes
Other Study ID Numbers: Nabi-1408
Study First Received: August 8, 2003
Last Updated: May 10, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Nabi Biopharmaceuticals:
Staphylococcal infection
Gram positive bacteria
Staphylococcus
Staphylococcus aureus

Additional relevant MeSH terms:
Birth Weight
Staphylococcal Infections
Body Weight
Signs and Symptoms
Gram-Positive Bacterial Infections
Bacterial Infections
Antibodies
Immunoglobulins
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 17, 2014